Evaluation of the safety, efficacy and acceptability of HMR 3647 (20 percent fine granules 1g sachet) in children with infections
Phase of Trial: Phase III
Latest Information Update: 07 Jul 2009
At a glance
- Drugs Telithromycin (Primary)
- Indications Bacterial infections; Dental infections; Otorhinolaryngological infections; Respiratory tract infections; Skin infections
- Focus Adverse reactions; Registrational
- Sponsors Sanofi
- 08 Apr 2009 Actual end date (May 2005) added as reported by ClinicalTrials.gov.
- 15 Dec 2006 New trial record.